Jennison Associates LLC Acquires 47,497 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Jennison Associates LLC increased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 61.4% in the 1st quarter, Holdings Channel.com reports. The firm owned 124,898 shares of the company’s stock after acquiring an additional 47,497 shares during the quarter. Jennison Associates LLC’s holdings in Amneal Pharmaceuticals were worth $1,552,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in AMRX. Kemnay Advisory Services Inc. acquired a new stake in Amneal Pharmaceuticals in the 4th quarter valued at approximately $26,000. Federated Hermes Inc. boosted its position in shares of Amneal Pharmaceuticals by 1,680.6% in the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after acquiring an additional 2,168 shares during the period. Comerica Bank grew its stake in shares of Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after acquiring an additional 1,957 shares during the last quarter. Spire Wealth Management increased its position in Amneal Pharmaceuticals by 66.6% during the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after acquiring an additional 1,023 shares during the period. Finally, Transamerica Financial Advisors LLC increased its position in Amneal Pharmaceuticals by 541.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after acquiring an additional 2,460 shares during the period. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock opened at $17.75 on Thursday. The stock has a market cap of $5.66 billion, a P/E ratio of 46.71 and a beta of 1.26. Amneal Pharmaceuticals, Inc. has a one year low of $7.66 and a one year high of $18.39. The stock has a fifty day moving average price of $15.36 and a 200 day moving average price of $14.00.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. The firm had revenue of $722.52 million for the quarter. Equities research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on AMRX shares. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Barclays increased their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. UBS Group lifted their target price on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Finally, Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $16.60.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Deborah M. Autor sold 34,819 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the sale, the director owned 93,660 shares of the company’s stock, valued at $1,211,960.40. The trade was a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.